Get started
Author

Eléonora De Maio

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
2017 · Jordi Remon, Jessica Menis, et al. · Clinical Lung Cancer · 99
PDF
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey
2018 · Antonin Levy, Corinne Faivre-Finn, et al. · European Journal of Cancer · 81
PDF
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study
2015 · Mélodie Dell’Ova, Eléonora De Maio, et al. · BMC Cancer · 39
PDF
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma
2017 · Edouard Auclin, Camille Bourillon, et al. · Clinical Genitourinary Cancer · 31
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6 th -7 th 2010"
2011 · Paolo A Ascierto, Eleonora De Maio, et al. · Journal of Translational Medicine · 29
PDF
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report
2012 · Ester Simeone, Eleonora De Maio, et al. · Journal of Medical Case Reports · 26
PDF
Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes
2022 · Gauthier Glemarec, Jean-Louis Lacaze, et al. · The Breast · 13
PDF
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)
2017 · L. Paz-Ares, B. Hasan, et al. · Annals of Oncology · 12
PDF
Diagnosis, biology and epidemiology of oligometastatic breast cancer
2021 · Jean-Louis Lacaze, Richard Aziza, et al. · The Breast · 9
PDF
A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial
2018 · S. Peters, S.J. Danson, et al. · Annals of Oncology · 9
Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution
2023 · Jean-Louis Lacaze, Ciprian Chira, et al. · Breast Cancer Research and Treatment · 3
PDF
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
2022 · Marcela Carausu, Matthieu Carton, et al. · Therapeutic Advances in Medical Oncology · 3
PDF
Evolution in neutrophil-to-lymphocyte ratio (NLR) among advanced soft tissue sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials
2017 · E. De Maio, N. Touati, et al. · Annals of Oncology · 3
Prognostic factors in hormone receptor positive oligometastatic breast cancer.
2023 · Lacaze Jean Louis, Bastien Cabarrou, et al. · Journal of Clinical Oncology · 2
PDF
Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study
2023 · Florent Puisset, Félicien Le Louedec, et al. · British Journal of Clinical Pharmacology · 2
PDF
320P Oligometastatic breast cancer incidence and clinical presentation at diagnosis: About 131 cases
2020 · J.L. Lacaze, C. Chira, et al. · Annals of Oncology · 1
PDF
Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey
2017 · L. Hendriks, C. Faivre-Finn, et al. · Annals of Oncology · 1
Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors
2015 · Sophie Cousin, Philippe A. Cassier, et al. · Pharmaceutical Medicine · 1
Stop Flow in Abdominal and Pelvic Relapses. Phase I Study and Phase Ii Preliminary. Sitilo National Project Data
2002 · other authors by SITILO National Project, RV Iaffaioli, et al. · Tumori Journal · 1
Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
2026 · Jean-Louis Lacaze, Bastien Cabarrou, et al. · The Oncologist
PDF
Triple-negative oligometastatic breast cancer: A retrospective cohort.
2026 · Jean Louis Lacaze, Bastien Cabarrou, et al. · Journal of Clinical Oncology
Abstract PS2-04-30: Enrolment of Patients with Metastatic Lobular Breast Cancer in Clinical Trials in the Multicenter ESME Cohort
2026 · E. De Maio, L. Chaltiel, et al. · Clinical Cancer Research
Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer
2026 · Tamasine Khadrouche, Mathilde Morisseau, et al. · The Breast Journal
3629 Tolerance of adjuvant radiotherapy after neoadjuvant chemo-immunotherapy for triple-negative breast cancer and impact of the immunotherapy regimen.
2025 · Ludovic Hernandez, Tamasine Khadrouche, et al. · Radiotherapy and Oncology
Patterns of progression in oligometastatic hormone receptor positive breast cancer after first-line systemic treatment at the metastatic stage.
2024 · Jean Louis Lacaze, Eleonora De Maio, et al. · Journal of Clinical Oncology
PDF
Works count: 39
Citation count: 365
H-index: 9
I10-index: 8
Year
Topic
Type